Michel Alvinerie

TL;DR: The comparative plasma disposition kinetics of IVM, MXD and DRM in cattle, characterized over 80 days post-treatment under standardized experimental conditions, is reported for the first time.

TL;DR: There was good correlation between concentration profiles of both compounds in plasma and target tissues (mucosal tissue, skin, and lung) and drug concentrations in target tissues remained above 1 ng/g for either 18 (IVM) or 38 (DRM) days post-treatment.

TL;DR: Xylazine bioavailability, as measured by the ratios of the areas under the intravenous and intramuscular plasma concentration versus time curves, ranged from 52% to 90% in dog, 17% to 73% in sheep and 40% to 48% in horse.

TL;DR: A unique case of naturally occurring gene invalidation is characterized, providing a putative novel model that remains to be exploited in the field of human therapeutics and that might significantly affect tissue distribution and drug bioavailability studies.

TL;DR: In this article, the ability of ivermectin, eprinomectin (EPR), abamectin (ABA), DOR, selamectin and moxidectin to inhibit the rhodamine123 efflux was measured in recombinant cells overexpressing P-gp.